Furthermore, fibroblast growth factor receptor (FGFR) and IL-6 signaling work in a concerted manner to activate STAT3 following erlotinib treatment in EGFR-mutant lung cancer cells, contributing to the resistance of drug-treated “oncogene-addicted cancer cells”35. Here, STAT3 is linked to lung carcinoma.